Company: AEMD
Filing Date: 2025-08-29
Form Type: S-1/A
Source: 0001683168-25-006537
Chunk: 57

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-29
Form: S-1/A
Chunk 57
---
90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest become “control
shares” to which the voting restrictions described above apply.

NRS 78.139 also provides that
directors may resist a change or potential change in control of the corporation if the board of directors determines that the change or
potential change is opposed to or not in the best interest of the corporation upon consideration of any relevant facts, circumstances,
contingencies or constituencies pursuant to NRS 78.138(4).

In addition, our authorized but
unissued shares of common stock are available for our Board of Directors to issue without stockholder approval. We may use these additional
shares for a variety of corporate purposes, including future public or private offerings to raise additional capital, corporate acquisitions
and employee benefit plans. The existence of our authorized but unissued shares of common stock could render more difficult or discourage
an attempt to obtain control of our company by means of a proxy contest, tender offer, merger or other transaction. Our authorized but
unissued shares may be used to delay, defer or prevent a tender offer or takeover attempt that a stockholder might consider in its best
interest, including those attempts that might result in a premium over the market price for the shares held by our stockholders. The Board
of Directors is also authorized to adopt, amend or repeal our Bylaws, which could delay, defer or prevent a change in control.

Nasdaq Listing

Our common stock is listed on The Nasdaq Capital Market
under the symbol “AEMD.”

Transfer Agent

The transfer agent and registrar for our common stock
is Computershare Investor Services. The transfer agent’s address is P.O. Box 30170, College Station, TX 77842.

| 33 |

<div align='center'>DESCRIPTION OF SECURITIES</div>

Company Offering

We are offering (i) up to 4,566,210 shares of our common stock or pre-funded warrants and (ii) warrants to purchase up to an aggregate of 4,566,210 shares of our common stock. Each share of common stock or pre-funded warrant is being sold together with a warrant to purchase one share of common stock. The shares of common stock or pre-funded warrants and accompanying warrants will be issued separately. We are also registering the shares of common stock issuable from time to time upon exercise of the pre-funded warrants and warrants offered hereby.

Common Stock

The material terms and provisions
of our common stock and